Adaptive Biotechnologies (ADPT)

Executive Summary

Adaptive Biotechnologies leverages its proprietary Immune Medicine Platform to decode T-cell and B-cell receptor genetics, translating immune system data into actionable clinical insights. The company's commercial clonoSEQ assay is a leading minimal residual disease (MRD) test for blood cancers, providing a recurring revenue stream and deep validation in hematologic malignancies. Additionally, Adaptive is advancing a therapeutic pipeline that includes TCR-based therapies and antibody candidates, with key programs in collaboration with partners like Genentech and Bristol Myers Squibb. Recent pipeline progress includes Phase 2 trials for mosunetuzumab in DLBCL and bendamustine+rituximab in lymphoma, as well as a Venetoclax combination in CLL. The company's platform also underpins drug discovery through its discovery engine for neoantigen-targeted TCRs. Despite near-term revenue growth driven by clonoSEQ, Adaptive faces competitive pressure in MRD testing and requires validation of its therapeutic programs to unlock significant value.

Upcoming Catalysts (preview)

• Q2 2027Potential FDA approval for expanded clonoSEQ indication in solid tumors or new disease40% success
• Q4 2026Data readout from Phase 2 mosunetuzumab trial in DLBCL (NCT06828991)30% success
• Q3 2026New partnership or licensing deal for TCR-based therapeutic candidates50% success